{"name":"Vifor Fresenius Medical Care Renal Pharma","slug":"vifor-fresenius-medical-care-renal-pharma","ticker":"","exchange":"","domain":"viforfreseniusmedicalcarerenalpharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Difelikefalin Injection","genericName":"Difelikefalin Injection","slug":"difelikefalin-injection","indication":"Moderate-to-severe pruritus in patients with chronic kidney disease on hemodialysis","status":"phase_3"}]}],"pipeline":[{"name":"Difelikefalin Injection","genericName":"Difelikefalin Injection","slug":"difelikefalin-injection","phase":"phase_3","mechanism":"Difelikefalin is a selective agonist of the peripheral kinin B1 receptor that reduces pruritus by modulating inflammatory pathways in patients with chronic kidney disease.","indications":["Moderate-to-severe pruritus in patients with chronic kidney disease on hemodialysis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPalBjaXNoWVkxWUhoRVNtR1dxZlBUdDdHb0ZWUW1UQlB3SV9qNm92UkZSaHBjR0U2WkxHVXp6ZERRT1FXQjk0TkVsUFNWeFNHRGtCaG1tR2dSMDB4NERFdEJHeWNvVGZFUmU0RTBrTW9VY2xjMTZudzRfWUdlLTVrZUcxeTBGVUtkbE90TUJTUVVOM3ZHRnJGMkJ0ZFQzc0xNY3FZRUE1cU43cGRFdHZTUlpNNlM3aUlmTWZ0bU13?oc=5","date":"2024-11-17","type":"regulatory","source":"www.hoganlovells.com","summary":"FDA denial of Vifor Velphoro petition shines new light on NCE interpretation - www.hoganlovells.com","headline":"FDA denial of Vifor Velphoro petition shines new light on NCE interpretation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1wYWlyaTJNNjB3UGxyRkxkMmtNUjAwS2NFMFR0UU5RejFxS0ViSzROQS1RWVV1d01aRDk2NFkydUNpZFhHQTJWaDJwVjNjUnFmdmc4aFd3aXBicFRvWjFaV2d3RjJmTHNVM3VaanZLNF9CZ0ZWSnA4?oc=5","date":"2023-06-01","type":"pipeline","source":"Global Biotechnology Company","summary":"Global Biotechnology Company - Global Biotechnology Company","headline":"Global Biotechnology Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPMzMzTEo4Tjg1MXZsVTBqcUpmUVpSS0NLY01LWHFSdjQ4VDNPdkR4OEdOZC0xOWNwZ2dsTzZRUWYyTlNEc3FQRk52d1Zpb0ZSc1VIcGkwNDJrX3BMMk5NZW1fV1lPZy1HLW9VWWxmWHJrRXpES3BFbXVlOWRTeHI2V0RtcUF6TG4wWm1rb0trbVI0SVRlelZBYW1EdjdwYmt2LUpwRU84dC1kVEtjVjMtY0xiV0IwZzRldXBiTHJMdWtKeW1DZGs2WVFFLXp5U2JKVzlYRHJqNW9NM043bldITXd6NFFDZmJ2NVRJbE9HaFd4Y2RvNzJ2ejg4VlhCSzFqSWRKRUZ0R1FMVHh1bHBkbQ?oc=5","date":"2023-05-18","type":"pipeline","source":"prnewswire.com","summary":"Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus - prnewswire.com","headline":"Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNRFg0Vm1TbmIxd1RacC1nM1JuRmtpaXRQZU52b3lIZE5ISmlZUTJTeDFoM0dzZ3RYZzdLY1lzZmRrZ1Bra2hvUURjbFhsQ2dKNGR5UVN1S0RuTW96Ymo3SFJTSXpHci11Y3RWOTRXMHVkWXU5b1Q5bm1qUDFfNE1OeWg1QkxMdG9XQ2Q1VzIySUhMU1NVOXY0cWNCS3kyS3hjMDkwUFhsVnJaa29Qcnk4cDc5RXFyTHJCUUhGQjlMU0otQ2tpZVV3cGVHck9TQQ?oc=5","date":"2022-12-14","type":"regulatory","source":"businesswire.com","summary":"Cancellation of remaining publicly held registered shares of Vifor Pharma AG - businesswire.com","headline":"Cancellation of remaining publicly held registered shares of Vifor Pharma AG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOZFhjck84N3I4OW1TRndjU05wUUdxQmxyN0Y3NW5zakE1bGZFcFluZjQ5UWY1X1FVcThnVUkxbGR2Szd0cElsck1VLUlHOW9OUWo1cktnUlZteG94MnpyRlVZZ1lqemh5WWJYT1E5ZThTbXEwTFFUZzh2VkVYdzJJZ2EwU1d1c2lBanFOZk5tcV9BemNKNkVFcEJGODI?oc=5","date":"2022-08-23","type":"patent","source":"Fierce Pharma","summary":"Sorry, Teva: CSL Vifor scores patent win to hold off proposed Velphoro generic - Fierce Pharma","headline":"Sorry, Teva: CSL Vifor scores patent win to hold off proposed Velphoro generic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9ubkp2WmFSSkhOTXU0SThPWWw4dWw2M19WZ1Y3R25weXBpbHIxeWE1LVdHOW1ZcmUtSjRkS21JUzZycUNQYWhYeDYyVVJMdW9nX2M1UWlNeUFiME9Kd2E3S1U4ak5QM194RmcyZnItWlVLdHdpMEFTTjJUZw?oc=5","date":"2021-09-09","type":"trial","source":"Clinical Trials Arena","summary":"Korsuva (difelikefalin) for the Treatment of Pruritus Associated with Chronic Kidney Disease - Clinical Trials Arena","headline":"Korsuva (difelikefalin) for the Treatment of Pruritus Associated with Chronic Kidney Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZWZNZEE1RXh1cDRMY3BzOVpNSG9MTzZSNk96djdVaXM5Q2EzU2RHeTQtcEIzdlJjRUg2NGlDd1BUMGMyU0YtSm1IV0JFdDBVcmlsZmU1U19abnd1ZnFtRURUd1AyZ3VtYTJrRzZoZXRocTJqb3hodmk0SGs1VWQtWE1fV0RweE44MjVsQUtTZVZrUDNBa1hfZ0xnVXJiOXh0M2tfMThQOVlqZw?oc=5","date":"2020-10-21","type":"deal","source":"European Biotechnology Magazine","summary":"Vifor Pharma in US$100m licence deal with Cara Therapeutics - European Biotechnology Magazine","headline":"Vifor Pharma in US$100m licence deal with Cara Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOVFl2aEt6eHcxVmpEeEdqNFkyX1FBUENUMnhNejE1cE1taTBzZlJHX2dDRXV2a3pfVkZmLW44VFB2V3U1ZFhCZTlyUHl4TXNuNDV0VHpmbnBkdmpPYzlWM0ZtY2FCaWlGNF9Jemc5blVadzlSM0pfOFQtanQtc2VLWU5hNTVBRzJlNFRYWjFocU1xaVp5LWpHczZnUGVJaVJQM3A2bnlMZDR0Z3lQbWd0a2FjaVk5MU0?oc=5","date":"2020-10-20","type":"deal","source":"BioSpace","summary":"Vifor Pharma and Cara Expand Licensing Deal for Late-Stage Kidney Disease Drug Korsuva - BioSpace","headline":"Vifor Pharma and Cara Expand Licensing Deal for Late-Stage Kidney Disease Drug Korsuva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPQmxQRjBYODdPOXFkcmdNNUtPNVdJQmJoQXZ1Z0pwN085R0dwV1B6ZGRCWDVBUndCaWFEUHd1QVlVQ20zNmxidTB0Zm9aUmM3SW9zSjhKbWFhWWthOXdpbjZtQ1UxMUMyamZWeVhkMzVPSHZxRzNoUDZYb2FJZjRlUEhWUUs?oc=5","date":"2020-02-20","type":"pipeline","source":"Pharmaceutical Technology","summary":"Vifor Pharma and Fresenius Kabi form joint venture in China - Pharmaceutical Technology","headline":"Vifor Pharma and Fresenius Kabi form joint venture in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZ19RZDZsZV9rSERfTlVZQWdMQ1h0aGdXNFFYdFUwdkd5VEo3dUpLUHZINkxlb251aHYtOTVTU2l0YjdMSUg3dDV6XzMzRm1XOEJSY1k5SnVsVjFDUmJNS2FrUnNVWlhNUlI2cG5WVUZVS1VGUm9odVdDV2VMaGRYWWRXM1NSZE5QSlVVaXlwVWJQTXY3Vjl4VFIzLTd4TzdLbXZkT1RRallVVlVlVHI0Vy1GSjl3alUx?oc=5","date":"2018-05-23","type":"deal","source":"Fierce Biotech","summary":"Cara signs $540M deal with Fresenius and Vifor Pharma to commercialize Korsuva - Fierce Biotech","headline":"Cara signs $540M deal with Fresenius and Vifor Pharma to commercialize Korsuva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOR1JxNEhxVWVSVlhGZ0VfWVV0X0Y5djJIRWhzVG5WZFRrMDdqcExRdjFlekZxT29uZ2ZSLW9VVWUzblZ2YlM3VzE2OUpmRkNoZlpNVDQzYS11alZKWEU0WFhlOUdlTXNFbVJQVzNEZDRJM2Mya0g4YmRtMGpoMFNMS3RTUDJCMkRWVGdnVmdmR1FGN1lJZHpzUkltQkNaRlhVMlVuRFF2dlFreUFFOU9SNVRidlN3bEt5eFl1UTc5eThkQ1lKQUtGeU5NN3N5N3F4VVBQM3R6eTdjWXdUNWI3UnFocUVoQS1fWWEzMXE2YjlFcDcxWjZpY3hR?oc=5","date":"2016-05-09","type":"pipeline","source":"OPKO Health, Inc.","summary":"Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO’s RAYALDEE - OPKO Health, Inc.","headline":"Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO’s RAYALDEE - OPKO Health, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQVlM2UjVwR3JyRUJfbWo1c2pEaDQta3hCRWVIb3Q4SmlYbllfaFRFRGFVR1FoLVp3NlJINjgwYVltVTBsZkxaWHZ3M0RleHBGeUhlWmZhTGJCYjMwMmdlUmFDVldpXzZpSEZmZmlWSFBaSUQwVldCRkNNNjRBREltcUxZMmZTRGZYY19PZXJVd196MngxQlNlWnhtb2xMY2Nx?oc=5","date":"2014-08-28","type":"regulatory","source":"BioPharma Dive","summary":"Velphoro wins EU approval for treating hyperphosphalemia - BioPharma Dive","headline":"Velphoro wins EU approval for treating hyperphosphalemia","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}